None
Quote | NextCure Inc. (NYSE:NXTC)
Last: | $ |
---|---|
Change Percent: | -2.82% |
Open: | $46.69 |
Close: | $45.15 |
High: | $46.81 |
Low: | $44.70 |
Volume: | 147,436 |
Last Trade Date Time: | 02/12/2020 04:42:13 pm |
News | NextCure Inc. (NYSE:NXTC)
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Message Board Posts | NextCure Inc. (NYSE:NXTC)
Subject | By | Source | When |
---|---|---|---|
NextCure Presented NC410 Data at the Extracellular Matrix | conix | investorshub | 06/27/2022 3:36:36 PM |
* * $NXTC Video Chart 11-05-2019 * * | ClayTrader | investorshub | 11/05/2019 10:15:30 PM |
Buying 78... stop 64 | europtiger | investorshub | 11/05/2019 7:05:21 PM |
Short | stock1ace1 | investorshub | 11/05/2019 5:40:36 PM |
These can be tricky when they keep halting | PennyDad | investorshub | 11/05/2019 5:07:38 PM |
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...